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Angiogenesis is essential for development, growth and advancement of solid tumours. Interferon-g-inducible protein 10 (IP-10)
regulates lymphocyte chemotaxis, mediates vascular pericyte proliferation and acts as an angiostatic agent, thus inhibiting tumour
growth. This prompted us to study the clinical implications of IP-10 expression related to angiogenesis in uterine cervical cancers. The
levels of IP-10 decreased with advancement, and the prognosis of the 30 patients with low IP-10 expression in uterine cervical
cancers was poor (66%), whereas the 24-month survival rate of the other patients with high IP-10 expression was 90%. Furthermore,
IP-10 levels significantly reverse-correlated with vascular endothelial growth factor (VEGF) levels in uterine cervical cancers.
Interferon-g-inducible protein 10 might work on suppression of angiogenesis associated with VEGF in advancement, and can be
recognised as a prognostic indicator. Furthermore, IP-10 activation might be effective on the suppression of regrowth or recurrence
after intensive treatment for advanced cervical cancers.
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Angiogenesis is essential for development, growth and advance-
ment of solid tumours (Folkman, 1985). Angiogenic factors from
tumours induce and activate matrix metalloproteinase, plasmino-
gen activator, collagenase and other enzymes in endothelial cells
(ECs). The enzymes dissolve basement membrane of ECs, after
which the ECs proliferate and migrate under the influence of
angiogenic factors. Angiogenic factors induce production of
integrins in the ECs. The ECs then form immature capillary tubes.
Specific angiogenic factors interacting with specific angiogenic
inhibitors produce specific angiogenesis in each tumour. The
angiogenic factors vascular endothelial growth factor (VEGF)
(Fujimoto et al, 1998d,a, 1999a, 2001, 2004), thymidine phosphory-
lase identified with platelet-derived EC growth factor (Fujimoto
et al, 1998b,c, 1999b,c, 2000a) interleukin (IL)-8 and basic
fibroblast growth factor (bFGF) along with the angiogenic
transcription factor ETS-1 (Fujimoto et al, 2002b) interacting with
angiogenic inhibitors work on angiogenesis.
We have reported the positive correlation between microvessel
counts and IL-8, and that IL-8 works as an angiogenic factor. There
was a significant difference in IL-8 levels between early-stage and
late-stage uterine cervical cancers. The prognosis of the higher
group was radically poorer than that of the lower group. This
indicates that IL-8 might be a prognostic indicator as an
angiogenic factor supplied from macrophages within and around
the tumour (Fujimoto et al, 2000b, 2002a). The expression of VEGF
was correlated with microvessel density in uterine cervical cancers.
The levels of VEGF and VEGF165 and VEGF121 mRNAs were
remarkably higher in some stages II and III/IV adenocarcinomas
of the cervix than in other cases including normal cervices.
Therefore, the elevation of VEGF165 and VEGF121 might contribute
to the relatively late advancing via angiogenic activity in some
adenocarcinomas of the cervix (Fujimoto et al, 1999a, 2004). The
expression of basic FGF was significantly higher in advanced
primary uterine cervical cancers, regardless of histological type.
This status might contribute to the acceleration of growth,
invasion, and metastasis with neovascularization in advanced
uterine cervical cancers (Fujimoto et al, 1995, 1997a,b).
Specific angiogenic inhibitors have not been well known in
uterine cervical cancers. Among angiogenic inhibitors, interferon-
g-inducible protein (IP-10) is a member of the CXC chemokine
family, whose members have four highly conserved cysteine
amino-acid residues, with the first two cysteines separated by one
non-conserved amino-acid residue, hence the name CXC (Rollins,
1997), that has been shown to induce chemotaxis of activated
T cells and to inhibit angiogenesis (Strieter et al, 1995). It is
produced by activated monocytes, fibroblasts, ECs, epithelial
cells and keratinocytes. Interferon-g-inducible protein 10 binds
to a seven-transmembrane G protein-coupled receptor, CXCR3,
expressed on activated T cells, leading to chemotaxis (Loetscher
et al, 1996). Downregulation of the angiostatic chemokine IP-10
has been found to be a factor in the development of idiopathic
pulmonary fibrosis (Keane et al, 1997) and endometriosis
(Yoshino et al, 2003). On the other hand, the overexpression of
IP-10 in human lymphoma grown in nude mice leads to
spontaneous regression directly related to impaired angiogenesis
(Sgadari et al, 1996a). This has been substantiated further in model
systems of human non-small cell lung cancer tumourigenesis in
severe combined immunodeficiency mice (Arenberg et al, 2001).
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sRetroviral gene transfer of IP-10 inhibited growth of human
melanoma xenografts in an angiogenesis-dependent manner
(Feldman et al, 2002).
This prompted us to study the expression manner of IP-10
interacting with various angiogenic factors, VEGF (Boulday et al,
2006), IL-8 (Elner et al, 2006), IL-12 (Sgadari et al, 1996b), TNF-a
(Gottlieb et al, 2005) according to various clinical backgrounds of
uterine cervical cancer patients, to know the clinical implications
of IP-10 in uterine cervical cancers.
MATERIALS AND METHODS
Patients
Informed consent for the following studies was obtained from all
patients and the Research Committee for Human Subjects, Gifu
University School of Medicine. Sixty patients ranging from 26 to
78 years of age with uterine cervical cancers (22 stage-I cases, 26
stage-II cases, 12 stage-III cases; and 47 squamous cell carcinomas,
13 adenocarcinomas) underwent curative surgery at the Depart-
ment of Obstetrics and Gynecology, Gifu University School of
Medicine, between December 1998 and January 2004. None of the
patients had received any therapy before uterine cervical cancer
tissue was taken. A part of each tissue of uterine cervical cancers
was snap-frozen in liquid nitrogen to determine IP-10, IL-8, and
VEGF and a neighbouring part of the tissues was submitted
for histopathological study including immunohistochemical
staining for IP-10. The clinical stage of uterine cervical cancers
was determined by International Federation of Obstetrics and
Gynecology (FIGO) classification (International Federation of
Obstetrics and Gynecology (FIGO) News, 1989).
Immunohistochemistry
Sections (4mm) of formalin-fixed paraffin-embedded tissues of
uterine cervical cancers were cut with a microtome and dried
overnight at 371C on a silanised-slide (Dako, Carpinteria, CA,
USA). Samples were deparaffinised in xylene at room temperature
(RT) for 80min and washed with a graded ethanol/water mixture
and then with distiled water. Immunohistochemical staining for
factor VIII-related antigen and CD34, which are synthesised by
vascular ECs, are specific for the ECs of blood vessels (Bell and
Flotte, 1982) and are useful for detecting tumour angiogenesis
(Weidner et al, 1991). The samples were soaked in a citrate buffer,
and then microwaved at 1001C for 10min. The protocol for a
DakoCytomation LSABþ System-HRP (Dako) was followed for
each sample. In the described procedures, goat anti-human IP-10
(R&D Systems, Minneapolis, MN, USA), rabbit anti-factor VIII-
related antigen (Zymed, San Francisco, CA, USA) and mouse CD34
(Dako) were used at dilutions of 1:25, 1:2 and 1:40, respectively,
as the first antibodies. The addition of the first antibody, goat anti-
human IP-10, rabbit anti-factor VIII-related antigen or mouse
CD34, was omitted in the protocols for negative controls of IP-10,
factor VIII-related antigen and CD34, respectively.
Vessels were counted in the five highest density areas at  200
magnification (using a combination of  20 objective and  10
ocular, 0.785mm
2field
 1) by blinded investigators. Microvessel
counts were expressed as the mean numbers of vessels in the five
highest density areas (Maeda et al, 1996). Microvessel density was
evaluated by the counting of microvessels.
Enzyme immunoassay for determination of IP-10, IL-8 and
VEGF antigens
All steps were carried out at 41C. Tissues of uterine cervical
cancers (wet weight: 10–20mg) were homogenised in HG buffer
(5mM Tris–HCl (pH 7.4), 5mM NaCl, 1mM CaCl2,2 m M
ethyleneglycol-bis-[b-aminoethylether]-N,N,N0,N0-tetraacetic acid,
1m M MgCl2,2 m M dithiothreitol, 25mgml
 1 aprotinin, and
25mgml
 1 leupeptin) with a Polytron homogenizer (Kinematics,
Luzern, Switzerland). This suspension was centrifuged in a
microfuge at 12000r.p.m. (10000g) for 3min to obtain the
supernatant. The protein concentration of samples was measured
by the method of Bradford (Bradford, 1976) to standardise IP-10,
IL-8 and VEGF antigen levels.
Interferon-g-inducible protein 10, IL-8 and VEGF antigen levels
in the samples were determined by a sandwich enzyme immuno-
assay using a Human IP-10 Quantikine (R&D Systems), a human
IL-8 Quantikine (R&D System) and a human VEGF Assay Kit-IBL
(Immuno Biological Laboratories, Gunma, Japan), respectively.
The levels of IP-10, IL-8 and VEGF were standardised with the
corresponding cellular protein concentrations.
Western blot analysis for IP-10
Tissues (wet weight: 10–20mg) were homogenised in a WB–HB
buffer (10mM Tris–HCl (pH 7.4), 150mM NaCl, 0.5% Triton X-100
and 0.2mM phenylmethyl sulphonyl fluoride) with a Polytron
homogenizer (Kinematics, Luzern, Switzerland). The protein
concentrations of samples were measured by protein assay
(Bio-Rad, Hercules, CA, USA). Each sample (25ml) containing
10mgo fp r o t e i nw a sa d d e dt o2 5mlo fas a m p l eb u f f e r( 1 2 . 5m M Tris–
HCl (pH 6.8), 2% glycerol, 0.4% SDS and 1.25% 2-mercaptoethanol)
and analysed by 20% SDS–PAGE under nonreducing condition.
The gel was transferred to a nitrocellulose membrane (Hybond
ECL Western; Amersham, Arlington Heights, IL, USA). The
membrane was blocked with 5% skim milk in a blocking buffer
(20mM Tris–HCl (pH 7.6), 137mM NaCl and 0.1% Tween-20),
incubated with rabbit anti-human IP-10 antibody (1:2000) (R&D
Systems) for 60min at RT, washed and then incubated with
peroxidase-linked species-specific whole antibody, anti-rabbit
immunoglobulin from a goat (1:5000; Santa Cruz Biotechnology,
Santa Cruz, CA, USA) for 60min at RT. After sequential washing
with blocking buffer, PBS with 0.1% Tween 20 and PBS, signals
were developed using ECL plus (GE Healthcare Bio-Sciences AB,
Uppsala, Sweden) and X-ray film was exposed on the membrane at
RT for 10min. Bands on the exposed film were captured with a
Fuji Image Analyzer LAS-1000 and the intensity was measured
with NIH-image (National Institutes of Health, Bethesda, MA
USA). The IP-10 levels as the arbitrary unit (AU) determined by
Western blot analysis for IP-10 were calculated as follows: IP-10
levels by Western blotting¼the intensity of IP-10 100/the
intensity of b-actin.
Statistics
Interferon-g-inducible protein 10, IL-8 and VEGF were measured
from three parts of the same tissue in triplicate. Statistical analysis
was performed with Student’s t-test. Differences were considered
significant when Po0.05. Correlation evaluations between VEGF
and IP-10 levels were analysed by Pearson’s product–moment
corelational coefficient. Positive correlation was considered
significant when Po0.05.
RESULTS
Interferon-g-inducible protein 10 was diffusely located in the
cancer cells, but not in the stromal cells of uterine cervical cancer
tissues in all cases given, as shown in Figure 1 for a representative
case (71-year-old patient, stage IIb, squamous cell carcinoma).
Interferon-g-inducible protein 10 levels significantly reversely
correlated with microvessel counts by immunohistochemical
staining for factor VIII-related antigen (MVC-F8) and by staining
for CD34 (MVC-CD34) (r¼ 0.544, Po0.001 and r¼ 0.612,
Po0.001, respectively) as shown in Figure 2.
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ELISA of six representative cases are shown in the left panel of
Figure 3. There was a significant positive correlation between the
IP-10 levels determined by Western blotting and ELISA as shown
in the right panel of Figure 3. In place of the Western blotting,
ELISA can be useful to determine the IP-10 levels reliably.
Interferon-g-inducible protein 10 expression did not demon-
strate any significant difference according to histopathological
type or lymph node metastasis, as shown in Figure 4. Interferon-
g-inducible protein 10 levels significantly decreased with advance-
ment (between stages I and II, Po0.001; between stages I and III,
Po0.001; and between stages II and III, Po0.05) as shown in
Figure 4. The 60 patients were divided equally in two, at the
median value of 140pgmg
 1 protein, to form the low IP-10
and high IP-10 groups. The prognosis of the 30 patients with high
IP-10 expression in uterine cervical cancers was good, whereas the
24-month survival rate of the other 30 patients with low IP-10
expression was significantly poorer, as shown in Figure 5.
Interferon-g-inducible protein 10 levels reversely (r¼ 0.564,
Po0.01) correlated with VEGF levels, as shown in Figure 6, but
not with IL-8 levels in uterine cervical cancers (data not shown).
DISCUSSION
In the present study, IP-10 reversely correlated with microvessel
counts and might act as an angiostatic agent in uterine cervical
cancers. Interferon-g-inducible protein 10 expressed in the cancer
cells decreased with tumour advancement, and downregulated
IP-10 correlated with poor patient prognosis in uterine cervical
cancers. This indicates that IP-10 works on angiogenesis as an
angiogenic inhibitor in uterine cervical cancers. Furthermore,
we were interested in how IP-10 interacts with angiogenic factors
specific to uterine cervical cancers.
Interferon-g-inducible protein 10 is identified as one of the
TNF-regulated products in keratinocytes (Sgadari et al, 1996b)
and it contributes to the antitumoural effects of IL-12 through
the recruitment of activated T cells, NK cells, monocytes and
macrophages as well as through its inhibitory effects on tumour
vasculature (Elner et al, 2006). Human retinal pigment epithelial
cells produced very high levels of IP-10 in response to either IL-1a
or TNF-a, in the presence of IFN-g (Boulday et al, 2006).
Interferon-g-inducible protein 10 potently inhibits angiogenesis,
working in a dose-dependent manner to inhibit both IL-8 and
bFGF-induced endothelial chemotaxis (Strieter et al, 1995).
Interferon-g-inducible protein 10 is expressed in some diseases
in association with VEGF. It is reported that VEGF may also play a
major role to augment the expression of IP-10 in T cells (Feldman
et al, 2002). Interferon-g-inducible protein 10 also inhibits the
proliferation of vascular ECs via IP-10 receptor CXCR3 expressed
in ECs (Lasagni et al, 2003). Interferon-g-inducible protein 10
inhibits VEGF-induced EC tube formation concomitant with
IP-10 Negative control
Figure 1 Immunohistochemical staining for IP-10 in uterine cervical
cancers (original magnification  100). A representative case of squamous
cell carcinoma of the uterine cervix. Goat anti-human IP-10 (R&D Systems,
Minneapolis, MN, USA) was used at a dilution of 1:50 as the first antibody.
Dark brown staining represents positive for IP-10 antigen.
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Figure 2 Correlation between microvessel counts and IP-10 in uterine
cervical cancers. Closed circles, microvessel counts by immunohistochemical
staining for factor VIII-related antigen (MVC-F8); open circles, microvessel
counts by immunohistochemical staining for CD34 (MVC-CD34).
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Figure 3 Correlation between IP-10 levels determined by Western blotting and ELISA. The bands of Western blots of the representative six cases are
shown. Representative cases are shown in Figure 4 using n. AU, arbitrary units of IP¼10.
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growth factor augments the effect of IFN-g on the induction of
IP-10 mRNA and protein expression in ECs, and Chinese
hamster ovary cells designed to secrete VEGF were injected
subcutaneously into the skin of nude mice and found to mediate a
time-dependent increase in IP-10 mRNA (Feldman et al, 2002).
Therefore, angiogenic factors specific to IP-10 might be IL-8, bFGF
and VEGF.
Among angiogenic factors specific to IP-10, angiogenic factors
specific to uterine cervical cancers seem to be IL-8 and VEGF. In
the present study, IP-10 levels reversely correlated with VEGF
levels, but not with IL-8, in uterine cervical cancers. The biological
pathway of IP-10 induction by VEGF as a homostatic regulation
might be lost with tumour advancement, resulting in drastic
tumour angiogenesis that accelerates tumour advancement.
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